EGFR mutations & deletions
HER2 (ERBB2) activating mutations
Our mission is to advance precision medicine through democratizing NGS globally to enable testing locally, closer to cancer patients.
Most innovative NGS technology to deliver fast, automated NGS results from
Unparalleled track record and capability of partnering with pharma companies on companion diagnostics from development through regulatory approval, to bring new therapies
The only globally distributed NGS CDx solution, commercially available and reimbursed by government and private payors in US, EU, Asia, and Middle East, accelerating patient access to new therapy through local testing.
Our technology solves the challenges of routine biomarker testing in clinical oncology.
Oncomine Dx Target Test was first approved in 2017 and and is still the only commercially distributable multiple biomarker CDx test based on NGS, which can be implemented in new laboratories around the world. Oncomine Dx Express Test is currently under development for future regulatory submissions.
|Oncomine Dx Target Test* (Approved)||Oncomine Dx Express Test† (In Development)|
|Sample Type||FFPE||FFPE, plasma|
|Number of Genes||46 (EU & Japan), 23 (US and Korea)||46|
|Alteration Types||Mutations (single nucleotide variants, multi-nucleotide variants, insertions, and deletions)||Mutations, copy number variants, fusions|
|Instrument||PGM Dx||Genexus Dx - In development|
|Turnaround Time (Days)||
|Reimbursement Status||Reimbursed in most countries launched||In Development|
Oncomine Dx Target Test, is approved and reimbursed by government and commercial insurers in over 15 countries, covering more than 550 million lives globally.
ODxTT only available in specific countries. Contact us to learn more.
*For In Vitro Diagnostic Use.
†For investigational use only. The performance characteristics of this product have not been established.